develop
antivir
drug
vaccin
diagnost
marker
still
ambiti
challeng
clinic
virolog
past
decad
data
highthroughput
technolog
allow
rapid
develop
new
antivir
therapeut
strategi
thu
make
profound
impact
translat
research
current
preclin
studi
virolog
aim
evalu
dynam
composit
local
protein
platform
involv
variou
hostviru
interact
among
differ
possibl
approach
mass
spectrometrybas
proteom
increasingli
use
defin
protein
composit
subcellular
compart
quantifi
differenti
protein
express
among
sampl
character
protein
complex
analys
protein
posttransl
modif
review
current
knowledg
use
proteom
approach
studi
viral
persist
pathogen
particular
focu
recent
advanc
hepat
c
research
understand
hostviru
interact
recent
advanc
systemwid
analys
omic
technolog
genom
transcriptom
greatli
enhanc
system
evalu
gene
express
despit
use
genom
transcriptom
approach
certain
limit
first
gene
mutat
mrna
express
level
determin
quantit
often
mirror
real
situat
term
matur
protein
moreov
translat
posttransl
regul
affect
level
matur
protein
also
function
fact
effect
protein
structur
biolog
function
altern
splice
posttransl
modif
virushost
interact
easili
predict
genom
transcriptom
studi
light
mass
spectrometri
ms
base
proteom
uniqu
necessari
tool
systemwid
structur
function
analysi
effector
biolog
function
proteom
offer
great
varieti
applic
experiment
proteom
analysi
summar
three
major
step
sampl
prepar
ii
protein
separ
iii
identif
downstream
bioinformat
analysi
also
perform
data
process
fig
first
requir
success
proteom
analysi
appropri
specif
protein
sampl
enrich
fraction
techniqu
inde
mani
crucial
viral
lifecycl
step
associ
defin
subcellular
complex
moreov
attract
therapeut
target
prognost
marker
either
specif
cell
membran
compon
circul
biolog
fluid
low
concentr
ii
sampl
prepar
step
lead
complex
mixtur
differ
protein
proper
separ
mixtur
essenti
accur
identif
quantif
protein
ms
tradit
twodimension
gel
electrophoresi
consid
suitabl
protein
separ
method
past
year
techniqu
complement
quantit
applic
twodimension
differ
ingel
electrophoresi
dige
allow
analysi
rel
chang
protein
abund
among
differ
sampl
howev
owe
recent
technic
advanc
highresolut
nanoliquid
chromatographi
gradual
replac
dige
low
volum
low
flow
rate
nanoliquid
chromatographi
allow
analysi
protein
attomol
level
significantli
reduc
solvent
wast
enhanc
msbase
protein
identif
iii
ms
core
proteom
biolog
applic
ms
grown
exponenti
sinc
discoveri
matrixassist
laser
desorpt
ioniz
electrospray
ioniz
techniqu
protein
identif
primari
aim
ms
proteom
applic
difficulti
analys
mass
entir
protein
identif
perform
peptid
obtain
proteolyt
cleavag
develop
quantit
techniqu
extend
ms
applic
proteom
fact
highthroughput
rel
absolut
protein
abund
measur
possibl
liquid
chromatographym
configur
varieti
isotopemedi
approach
isotopecod
affin
tag
isotopecod
protein
label
accur
mass
time
tag
approach
isobar
tag
rel
absolut
quantit
stabl
isotop
label
amino
acid
cell
cultur
viral
replic
propag
caus
host
cellular
proteom
variat
identif
protein
whose
presenc
affect
presenc
viru
may
serv
either
diagnost
prognost
purpos
discoveri
novel
therapeut
target
fig
biomark
investig
normal
perform
biolog
fluid
serum
plasma
saliva
excel
exampl
observ
investig
wiederin
et
al
sera
human
immunodefici
dementia
patient
allow
identif
two
differenti
express
protein
prealbumin
gelsolin
earli
biomark
human
immunodefici
virusinduc
neurodegen
disord
interestingli
biomark
identif
also
obtain
tissu
cell
cultur
protein
sourc
exampl
analys
hepat
b
virusrepl
hepatoma
cell
line
itraq
approach
feng
et
al
identifi
apolipoprotein
apo
ai
glycoprotein
prognost
biomark
candid
hepat
b
virusassoci
hepatocellular
carcinoma
hcc
efficaci
antivir
agent
often
depend
abil
reach
viral
subcellular
nich
host
cell
differenti
proteom
also
prove
suitabl
tool
subcellular
local
virus
emmott
et
al
use
approach
studi
coronaviru
infecti
bronchiti
viru
infect
particular
silacbas
proteom
analysi
allow
identif
viral
protein
n
local
nucleolu
thu
open
new
avenu
develop
compound
target
infecti
bronchiti
viru
life
cycl
potenti
msbase
proteom
well
establish
function
structur
studi
complet
descript
viral
protein
form
infecti
particl
character
virushost
protein
interact
current
challeng
molecular
virolog
great
implic
translat
clinic
research
approach
proteinprotein
interact
analysi
tandem
affin
purif
coimmunoprecipit
coupl
msbase
proteom
elucid
sever
mechan
virus
exploit
host
molecular
machineri
benefit
well
host
countermeasur
fig
notabl
one
proteom
studi
lowdens
lipoproteinassoci
protein
identifi
hepat
c
viru
hcv
replic
complex
purif
thu
reveal
assembl
secret
lowdens
lipoprotein
particl
requir
viru
product
propag
million
person
worldwid
infect
hcv
infect
caus
chronic
liver
diseas
eventu
lead
cirrhosi
hcc
prognost
diagnost
marker
discoveri
current
standard
therapi
chronic
hepat
c
combin
peginterferon
ribavirin
result
sustain
virolog
respons
svr
half
patient
therapi
besid
rel
ineffici
also
often
associ
seriou
side
effect
novel
directact
antivir
treatment
target
viral
protein
recent
introduc
allow
increas
svr
rate
achiev
howev
efficaci
still
depend
combin
peginterferon
ribavirin
therefor
crucial
identifi
pretreat
earli
treatment
outcom
predictor
order
provid
consist
estim
svr
moreov
although
drug
repres
major
step
toward
hcv
erad
limit
select
drugresist
virus
reason
identif
novel
drug
target
host
factor
necessari
viru
life
cycl
remain
import
goal
near
futur
halt
hcv
infect
progress
proteom
led
improv
field
molecular
mechan
hcvinduc
pathogenesi
identif
marker
valuabl
discrimin
patient
respond
svr
respond
current
antivir
therapi
ii
fibrosi
cirrhosi
hcc
diagnosi
section
provid
exampl
recent
find
recent
compar
circul
lipoprotein
proteom
hcvinfect
patient
healthi
donor
observ
hcv
induc
impair
associ
apoai
lowdens
lipoprotein
particl
use
hcv
cellular
model
demonstr
apoailowdens
lipoprotein
associ
impair
occur
lipoprotein
gener
caus
viral
replic
interestingli
apoai
downregul
induc
signific
impair
hcv
product
thu
reinforc
notion
hcv
requir
host
lipoprotein
machineri
understand
molecular
mechan
hcvinduc
lipoprotein
gener
defect
perform
quantit
proteom
analysi
silaclabel
subcellular
fraction
demonstr
vitro
hcv
induc
ferritin
heavi
chain
fth
upregul
fth
cellular
determin
hcvinduc
secret
inhibit
importantli
neg
correl
ferritin
serum
level
found
patient
moreov
fth
express
found
requir
robust
hcv
infect
altogeth
result
provid
novel
molecular
explan
hcvinduc
hypobetalipoproteinaemia
liver
steatosi
could
use
develop
new
antivir
strategi
data
togeth
result
mention
underlin
hcvlipoprotein
interact
repres
attract
target
indirectact
antivir
develop
eleg
studi
perform
katz
laboratori
shed
light
earli
step
hcv
pathogenesi
mean
accur
mass
time
tag
amt
approach
analys
proteom
sequenti
liver
biopsi
specimen
hcvinfect
patient
andor
month
liver
transplant
gener
proteom
databas
highli
permiss
cell
contain
fulllength
hcv
replicon
allow
identif
mani
protein
lg
total
liver
biopsi
extract
use
liver
biopsi
specimen
patient
differ
grade
fibrosi
author
identifi
subset
protein
abl
indic
whether
patient
progress
sever
liver
diseas
posttransplant
includ
protein
involv
amino
acid
carbohydr
lipid
metabol
pathway
ii
immun
respons
ie
proinflammatori
acutephas
respons
cellular
recruit
iii
hepatoprotect
ie
associ
superoxid
cystein
glutathion
xenobiot
metabol
fibrogen
ie
link
epithelialtomesenchym
transit
process
observ
increas
proinflammatori
activ
impair
antioxid
defenc
suggest
patient
develop
signific
liver
injuri
experi
elev
oxid
stress
importantli
data
confirm
serum
metabolom
independ
cohort
hcv
patient
overal
find
demonstr
import
use
vitro
observ
assist
identif
protein
pathway
involv
hcvinduc
liver
diseas
progress
proteom
togeth
omic
approach
larg
appli
identifi
prognost
marker
antihcv
therapi
outcom
main
breakthrough
genom
trascriptom
studi
identif
singlenucleotid
polymorph
gene
code
interferon
ifn
ii
dysregul
liver
express
level
ifninduc
gene
regard
recent
perform
proteom
analysi
pretreat
liver
biopsi
specimen
patient
svr
nonrespond
patient
studi
confirm
presenc
invers
correl
level
ifnrel
gene
rate
svr
also
identifi
protein
involv
stress
respons
energi
metabol
put
prognost
factor
proteom
studi
laboratori
also
shown
posttransl
modif
anoth
sourc
prognost
marker
treatment
outcom
charg
modif
dihydroxyaceton
kinas
neg
regul
antivir
pathway
detect
liver
biopsi
specimen
phosphoryl
akt
kinas
protein
kinas
cfk
observ
peripher
blood
mononuclear
cell
mani
effort
identifi
prognost
diagnost
marker
made
serum
easili
access
biolog
fluid
may
reflect
immunolog
patholog
event
chronic
hcv
infect
despit
advantag
drawback
difficulti
find
lowabund
protein
owe
presenc
highabund
protein
albumin
immunoglobulin
etc
one
challeng
mani
effort
also
made
overcom
problem
regard
selditof
technolog
combin
chromatographi
separ
ms
analysi
repres
import
advanc
identifi
bloodcircul
marker
instanc
differ
pretreat
serum
protein
whose
level
significantli
differ
patient
svr
nonrespond
patient
identifi
approach
importantli
associ
serum
protein
level
clinic
biochem
characterist
stage
fibrosi
polymorph
viral
genotyp
led
accur
predict
treatment
respons
indic
combinatori
analysi
clinic
molecular
data
requir
achiev
reliabl
prognost
test
moreov
gangadharan
et
al
identifi
lowabund
plasma
protein
narrow
ph
rang
proteom
analys
hcv
patient
differ
degre
liver
fibrosi
among
new
candid
biomark
level
six
protein
lipid
transfer
inhibitor
protein
complement
complement
corticosteroidbind
globulin
apoj
found
decreas
invers
patient
fibrosi
grade
beretta
laboratori
extens
ms
analysi
larg
cohort
hcc
patient
perform
immunodeplet
abund
plasma
protein
multidimension
protein
separ
follow
sdspage
found
osteopontin
sensit
hcc
prognost
marker
approach
identifi
hcvrelat
hcc
biomark
attempt
nomura
laboratori
downstream
proteom
analysi
liver
biopsi
specimen
hcc
patient
author
investig
possibl
detect
serum
autoantibodi
direct
protein
found
overexpress
basi
find
approach
propos
serum
level
antibodi
potenti
biomark
earli
detect
hcc
hcvinfect
patient
altogeth
studi
provid
initi
evid
recent
develop
reliabl
proteom
approach
may
near
futur
allow
complet
character
hcv
patient
dysfunct
order
prevent
monitor
diseas
progress
achiev
viru
erad
